1. bookVolume 4 (2021): Issue 1 (June 2021)
Journal Details
License
Format
Journal
eISSN
2544-8978
First Published
30 May 2018
Publication timeframe
1 time per year
Languages
English
access type Open Access

A rare case of knee joint mucormycosis with pathological fracture after COVID-19 infection

Published Online: 13 Aug 2021
Volume & Issue: Volume 4 (2021) - Issue 1 (June 2021)
Page range: 9 - 15
Accepted: 23 Jul 2021
Journal Details
License
Format
Journal
eISSN
2544-8978
First Published
30 May 2018
Publication timeframe
1 time per year
Languages
English
Abstract

Mucormycosis is a fungal infection that generally occurs in patients with some degree of immunosuppression, such as patients with malignancies, diabetes, HIV infection, or patients who require the administration of immunosuppressive drugs.

The final diagnosis is established by collecting some tissue from the infectious process and isolating the fungus using lab cultures.

The treatment of mucormycosis is complex and consists of trying to reduce risk factors, rigorous surgical debridement, and specific antifungal treatment.

We present the case of a 54-year-old male patient with a background of SARS-COV2 infection (moderate form), that started 3 months prior to presentation to our hospital, initially treated at home.

The patient presented to the Orthopaedics Department of the University Emergency Hospital of Bucharest with pain and total functional impotence in his left knee as a result of a trauma that occurred about 2 months before the presentation to the hospital, at that moment with progressive worsening of the symptoms. Clinical and imaging examination established the diagnosis of pathological supra-intercondylar fracture of the left femur.

The purpose of this case report is to present the risk of infection with an opportunistic agent as a result of immunosuppression induced by COVID-19 or its treatment with immunosuppressive agents necessary to combat the inflammatory process. The patient presented with a moderate form of COVID-19 treated at home with nonsteroidal anti-inflammatory drugs and antibiotics to prevent a bacterial superinfection.

Mucormycosis remained a challenging situation for the physician, regardless of his medical specialty, both in terms of diagnosis and treatment. In this case, COVID-19 is one of the risk factors that contributed to the appearance of mucormycosis.

Keywords

1. 1.Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep. 2007 Nov;9(6):435-40. doi: 10.1007/s11908-007-0066-4.10.1007/s11908-007-0066-4 Search in Google Scholar

2. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F et al. Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15(9):1395-1401. doi: https://dx.doi.org/10.3201/eid1509.090334.10.3201/eid1509.090334 Search in Google Scholar

3. 3.Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012 Feb;54 Suppl 1(Suppl 1):S8-S15. doi: 10.1093/cid/cir864.10.1093/cid/cir864 Search in Google Scholar

4. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579.10.1086/432579 Search in Google Scholar

5. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. CurrOpin Infect Dis. 2004 Dec;17(6):517-25. doi: 10.1097/00001432-200412000-00003.10.1097/00001432-200412000-00003 Search in Google Scholar

6. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SC. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019 Jan;25(1):26-34. doi: 10.1016/j.cmi.2018.07.011.10.1016/j.cmi.2018.07.011 Search in Google Scholar

7. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, Simko JP, Winn BJ. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic PlastReconstr Surg. 2021 Mar-Apr 01;37(2):e40-e80. doi: 10.1097/IOP.0000000000001889.10.1097/IOP.0000000000001889 Search in Google Scholar

8. Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020 Sep 30;12(9):e10726. doi: 10.7759/cureus.10726.10.7759/cureus.10726 Search in Google Scholar

9. Monte Junior ESD, Santos MELD, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, Funari MP, de Moura EGH. Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report. Clin Endosc. 2020 Nov;53(6):746-749. doi: 10.5946/ce.2020.180.10.5946/ce.2020.180 Search in Google Scholar

10. Machouart M, Larché J, Burton K, Collomb J, Maurer P, Cintrat A, Biava MF, Greciano S, Kuijpers AF, Contet-Audonneau N, de Hoog GS, Gérard A, Fortier B. Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol. 2006 Mar;44(3):805-10. doi: 10.1128/JCM.44.3.805-810.2006.10.1128/JCM.44.3.805-810.2006 Search in Google Scholar

11. Ling H, Yuan Z, Shen J, Wang Z, Xu Y. Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinical pathogenic fungi: a meta-analysis. J Clin Microbiol. 2014 Jul;52(7):2573-82. doi: 10.1128/JCM.00700-14.10.1128/JCM.00700-14 Search in Google Scholar

12. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009 Jun 15;48(12):1743-51. doi: 10.1086/599105.10.1086/599105 Search in Google Scholar

13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.10.1016/S0140-6736(20)30183-5 Search in Google Scholar

14. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530.10.1093/cid/ciaa530 Search in Google Scholar

15. Rapp RP, McCraney SA, Goodman NL, Shaddick DJ. New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother. 1994 Nov;28(11):1255-63. doi: 10.1177/106002809402801109.10.1177/106002809402801109 Search in Google Scholar

16. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother. 1992 Oct;26(10):1253-61. doi: 10.1177/106002809202601014.10.1177/106002809202601014 Search in Google Scholar

17. Vossen MG, Thalhammer F. Effects of renal replacement therapy on antimicrobial therapy. Curr Clin Pharmacol. 2013 Feb 1;8(1):39-45.10.2174/1574884711308010006 Search in Google Scholar

18. Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2019 Jan;26(1):8-15. doi: 10.1053/j.ackd.2019.01.004.10.1053/j.ackd.2019.01.004 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo